CXCL4-platelet factor 4, heparin-induced thrombocytopenia and cancer (Q33401720)

26 July 2017

title

CXCL4-platelet factor 4, heparin-induced thrombocytopenia and cancer (English)

1 reference

heparin-induced thrombocytopenia

26 July 2017

1 reference

1 reference

Per Morten Sandset

1 reference

26 July 2017

publication date

1 April 2012

1 reference

26 July 2017

1 reference

26 July 2017

volume

129 Suppl 1

1 reference

26 July 2017

page(s)

S97-100

1 reference

Differentiation of certain platelet factors related to blood coagulation

26 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970026-9

7 January 2021

Chemokines: a new classification system and their role in immunity

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970026-9

7 January 2021

The chemokine system in experimental and clinical hematology

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970026-9

7 January 2021

The Functional Role of the ELR Motif in CXC Chemokine-mediated Angiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970026-9

7 January 2021

Platelet Factor 4: Production, Structure, and Physiologic and Immunologic Action

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970026-9

7 January 2021

The role of the CXC chemokines platelet factor-4 (CXCL4/PF-4) and its variant (CXCL4L1/PF-4var) in inflammation, angiogenesis and cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970026-9

7 January 2021

Angiostatic and chemotactic activities of the CXC chemokine CXCL4L1 (platelet factor-4 variant) are mediated by CXCR3.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970026-9

7 January 2021

Platelet factor 4 binds to glycanated forms of thrombomodulin and to protein C. A potential mechanism for enhancing generation of activated protein C

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970026-9

7 January 2021

Clinical practice. Heparin-induced thrombocytopenia

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970026-9

7 January 2021

Drug-induced immune-mediated thrombocytopenia--from purpura to thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970026-9

7 January 2021

Heparin-induced thrombocytopenia

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970026-9

7 January 2021

Immunobiology of heparin-induced thrombocytopenia

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970026-9

7 January 2021

Heparin-induced thrombocytopenia: a stoichiometry-based model to explain the differing immunogenicities of unfractionated heparin, low-molecular-weight heparin, and fondaparinux in different clinical settings

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970026-9

7 January 2021

Role of platelet surface PF4 antigenic complexes in heparin-induced thrombocytopenia pathogenesis: diagnostic and therapeutic implications

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970026-9

7 January 2021

Induction of monocyte tissue factor expression by antibodies to heparin-platelet factor 4 complexes developed in heparin-induced thrombocytopenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970026-9

7 January 2021

Temporal aspects of heparin-induced thrombocytopenia

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970026-9

7 January 2021

Heparin-induced thrombocytopenia: temporal pattern of thrombocytopenia in relation to initial use or reexposure to heparin

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970026-9

7 January 2021

The temporal profile of the anti-PF4/heparin immune response

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970026-9

7 January 2021

Studies of the immune response in heparin-induced thrombocytopenia

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970026-9

7 January 2021

Immune mechanisms in heparin-induced thrombocytopenia: no evidence for immunoglobulin M anti-idiotype antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970026-9

7 January 2021

Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970026-9

7 January 2021

Use of heparin during cardiopulmonary bypass in patients with a history of heparin-induced thrombocytopenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970026-9

7 January 2021

Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970026-9

7 January 2021

Antibodies to platelet factor 4-heparin after cardiopulmonary bypass in patients anticoagulated with unfractionated heparin or a low-molecular-weight heparin : clinical implications for heparin-induced thrombocytopenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970026-9

7 January 2021

IgG classification of anti-PF4/heparin antibodies to identify patients with heparin-induced thrombocytopenia during mechanical circulatory support.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970026-9

7 January 2021

Incidence and prognostic significance of thrombocytopenia in patients treated with prolonged heparin therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970026-9

7 January 2021

Heparin induced thrombocytopenia and thrombosis in a tertiary care hospital

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970026-9

7 January 2021

The incidence of heparin-induced thrombocytopenia in hospitalized medical patients treated with subcutaneous unfractionated heparin: a prospective cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970026-9

7 January 2021

The incidence of heparin-induced thrombocytopenia in medical patients treated with low-molecular-weight heparin: a prospective cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970026-9

7 January 2021

Cancer, thrombosis and heparin-induced thrombocytopenia

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970026-9

7 January 2021

Heparin-Induced Thrombocytopenia in Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970026-9

7 January 2021

Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970026-9

7 January 2021

An improved definition of immune heparin-induced thrombocytopenia in postoperative orthopedic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970026-9

7 January 2021

Failure of early heparin cessation as treatment for heparin-induced thrombocytopenia

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970026-9

7 January 2021

Delayed-onset heparin-induced thrombocytopenia and thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970026-9

7 January 2021

The HIT Expert Probability (HEP) Score: a novel pre‐test probability model for heparin‐induced thrombocytopenia based on broad expert opinion

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970026-9

7 January 2021

Evaluation of pretest clinical score (4 T's) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970026-9

7 January 2021

Prospective evaluation of the '4Ts' score and particle gel immunoassay specific to heparin/PF4 for the diagnosis of heparin-induced thrombocytopenia

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970026-9

7 January 2021

Strategies for the management of suspected heparin-induced thrombocytopenia: a cost-effectiveness analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970026-9

7 January 2021

Heparin-induced thrombocytopenia: a prospective study on the incidence, platelet-activating capacity and clinical significance of antiplatelet factor 4/heparin antibodies of the IgG, IgM, and IgA classes

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970026-9

7 January 2021

Laboratory testing for the antibodies that cause heparin-induced thrombocytopenia: how much class do we need?

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970026-9

7 January 2021

10.1016/S0049-3848(12)70026-9

Identifiers

DOI

1 reference

26 July 2017

1 reference